Design and Characterization of a Metalloproteinase Inhibitor-Tethered Resin for the Detection of Active MMPs in Biological Samples  by Hesek, Dusan et al.
Chemistry & Biology 13, 379–386, April 2006 ª2006 Elsevier Ltd All rights reserved DOI 10.1016/j.chembiol.2006.01.012Design and Characterization of a Metalloproteinase
Inhibitor-Tethered Resin for the Detection
of Active MMPs in Biological SamplesDusan Hesek,1,3 Marta Toth,1,2,3 Samy O. Meroueh,1
Stephen Brown,1 Huiren Zhao,2 Wael Sakr,2
Rafael Fridman,2,* and Shahriar Mobashery1,*
1Department of Chemistry and Biochemistry and
The Walther Cancer Research Center
University of Notre Dame
Notre Dame, Indiana 46556
2Department of Pathology
Protease and Cancer Program and





Matrix metalloproteinases (MMPs), zinc-dependent
endopeptidases, are implicated in tumor progression.
We describe herein the development of a resin-immo-
bilized, broad-spectrum synthetic MMP inhibitor for
selective binding of the active forms of MMPs from dif-
ferent experimental samples. We confirmed the activ-
ity-based binding of MMPs to the inhibitor-tethered
resin with purified human recombinant MMP-2, -9,
and -14, samples of cultured cells, and tissue extracts.
Our results show that only the free active MMPs, and
not the zymogens or MMP/TIMP (enzyme-protein in-
hibitor) complexes, bound specifically to the resin. In
our comparison of benign and carcinoma tissue ex-
tracts, we detected active MMP-2 and MMP-14 forms
only in the cancerous tissue samples, indicating that
a pool of the tumor MMPs is free of endogenous inhib-
itors (TIMPs), and is thus likely to contribute to proteo-
lytic events that precipitate tumor metastasis.
Introduction
Metastasis is the single most important clinical feature
associated with poor prognosis and survival in cancer
patients, resulting in mortality in over 90% of patients
[1]. Unfortunately, in spite of the significant advances
in the past two decades in our understanding of the ge-
netic and molecular processes that regulate cancer de-
velopment and progression, treatment options for the
prevention of cancer metastasis do not exist.
Tumor metastasis requires the activity of proteolytic
enzymes to hydrolyze extracellular matrix (ECM) com-
ponents and a variety of bioactive molecules, which to-
gether regulate tumor cell migration, invasion, and
growth. Matrix metalloproteinases (MMPs), a group of
at least 26 known enzymes, constitute a family of extra-
cellular zinc-dependent endopeptidases that are in-
volved in degradation of ECM components and other
bioactive non-ECM molecules, and thus are involved in
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3 These authors contributed equally to this work.many normal and pathological processes, including tu-
mor cell invasion and metastasis [2–5]. It is known that
the expression of the genes of many MMPs is upregu-
lated in human cancers, implicating their activity in can-
cer progression [6–9]. A plethora of studies in animal
models of experimental metastasis have shown that in-
hibition of activity or expression of members of the MMP
family significantly inhibits tumor growth, decreases
metastatic burden, and improves survival [2, 10–18].
However, recent evidence demonstrates that, in fact,
MMPs play complex roles in cancer progression. Thus,
while certain MMPs promote cancer progression, others
can act in an inhibitory way. This new evidence high-
lights the importance of identifying and characterizing
the expression and specific roles of active MMPs in
human tumors [19–21].
Virtually all of the inhibition studies of MMPs have
been carried out with broad-spectrum inhibitors. These
inhibitors were developed mostly as zinc-ion chelators,
and, as such, they inhibit a broad range of MMPs and of-
ten other related enzymes as well [12]. The initial suc-
cess of various broad-spectrum synthetic MMP inhibi-
tors in animal models of cancer metastasis and
angiogenesis [22, 23] prompted the implementation of
human clinical trials. Although some studies showed
promise, others have been disappointing [12, 16, 24].
Several reasons were postulated to explain the poor
performance of broad-spectrum MMP inhibitors in clin-
ical trials, including advance stage of disease of the pa-
tient population, side effects due to inhibition of closely
related enzymes such as the ADAMs (a disintegrin and
metalloproteinases), lack of specificity, toxicity, and in-
ability to assess inhibitory efficacy [12, 16, 24, 25]. An im-
portant aspect that has been lacking in all these studies
is the identification of specific MMPs (out of the 26
known) that are important for the disease progression.
Thus, determination of the protease profile for each can-
cer type, in particular the active form, will help to target
specific MMPs on an individual basis with specific/se-
lective inhibitors, avoiding unwanted side effects [26].
Profiling of MMP expression in cancer patients has
been limited to detection of gene or protein levels in tis-
sues and/or biological fluids. Although these methods
can provide important information on the relative levels
of MMPs during tumor progression they are not de-
signed to identify which MMP(s) are active and thus re-
sponsible for the proteolytic activity in cancerous tis-
sues. MMPs are produced as inactive zymogenic (also
known as ‘‘latent’’) forms. The zymogens have N-termi-
nal propeptides of approximately 80–90 amino acids
that block the active sites of the MMPs within the cata-
lytic domains. Removal of the propeptide by proteolytic
or nonproteolytic mechanisms results in zymogen acti-
vation and acquisition of catalytic competence [27–30].
Once active, the MMPs are specifically inhibited by en-
dogenous protease inhibitors, known as tissue inhibi-
tors of metalloproteinases (TIMPs) of which four,
TIMP-1 to TIMP-4, have been identified [31]. Binding of
TIMPs to the catalytic domain results in efficient inhibi-
tion of enzymatic activity [32]. It has been postulated
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380Figure 1. Inhibitor-Tethered Resins for Use
with MMPs
(A) The structure of the Batimastat (1) used in
the design of the inhibitor-tethered resin; the
site chosen for attachment to the resin is in-
dicated by the arrow. The inhibitor-tethered
resin (2) based on the structure of inhibitor
1. The Sepharose 6B resin is shown as its
monomeric building block in brackets.
(B) The stereoview of the water-accessible
Connolly surface constructed on the X-ray
coordinates of the catalytic domain of
MMP-12. The bound inhibitor, Batimastat
(1), is shown in capped-sticks representation
(C, N, O, S in white, blue, red and orange, re-
spectively). The catalytic zinc ion is shown
as an orange sphere deep in the active site,
a portion of which is visible from this per-
spective. The white arrow points to the sulfur
that will be the point of attachment to resin 2.
(C) Synthetic scheme for the preparation of
the three targeted resins 2, 5, and 6.that in cancer there exists an imbalance between active
MMPs and TIMPs, which may lead to excessive enzy-
matic activity and eventually promote metastasis [16,
24]. Thus, the presence of active MMPs depends on
both the rate of zymogen activation and the levels of en-
dogenous TIMPs. At present, there are no established
approaches to determine what MMP(s), among all the
members of the MMP family, is catalytically active and
free of TIMPs in cancer tissues. Knowing this informa-
tion would help the development of approaches aimed
at targeting the relevant MMPs for selective inhibition.
Here we report the development of an inhibitor-teth-
ered resin with a broad-spectrum inhibitor for MMPs.
The inhibitor that we have selected (the criteria for
choice are described below) for attachment to this resin
is Batimastat [10] (referred to here as inhibitor 1), which
is a potent and broad-spectrum MMP inhibitor. The tar-
geted resin is given as structure 2 (based on a variation
of 1) (Figure 1). This tool should be useful for monitoring
biological samples, including tumor tissues, for the
presence of active and uninhibited MMP.
Results and Discussion
Design of the Inhibitor-Tethered Resin
As the first prerequisite for designing the inhibitor-teth-
ered resin, it was important to select a broad-spectrumMMP inhibitor that would allow binding of multiple
MMPs. The second prerequisite was the availability of
crystal structures for the inhibitor bound to the active
sites of these MMPs for judicious selection of the point
of attachment of the resin to the inhibitor.
An extensive survey of all the existing X-ray structures
of MMP-inhibitor complexes from the RCSB database
(http://www.rcsb.org) was carried out by systematically
visualizing the complexes with the Sybyl 6.9.1 software
package (Tripos, Inc.). At the time of this effort, there
were 25 three-dimensional structures available for cata-
lytic domains of MMPs bound to various inhibitors. The
goal of this exercise was to find inhibitor-MMP com-
plexes in which the bound inhibitor contained a struc-
tural moiety that was solvent exposed. Furthermore,
we expected that the solvent-exposed site would be
synthetically accessible for facile structure alteration,
such that a linkage to a chromatographic resin through
this site could be made. The structure of the broad-
spectrum inhibitor 1 (Batimastat) bound to the catalytic
domain of MMP-12 [33, 34] met the above criteria. As
shown in Figure 1, the P10 moiety of the broad-spectrum
MMP inhibitor 1 was exposed to solvent in the complex
(shown by arrows in the structure of 1 in Figures 1A and
1B). This was chosen as the site of attachment to Se-
pharose 6B. A synthetically feasible modification of
this side chain was designed to allow chemoselective
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381Figure 2. Binding of Recombinant Gelati-
nases to the Inhibitor-Tethered Resin
(A) Time course of gelatinase binding. Latent
(pro-MMP-9 and pro-MMP-2) and active
(MMP-9 and MMP-2) recombinant gelati-
nases (10 nM) were incubated with or with-
out 20 ml resin 2 in 0.5 ml CB buffer. At vari-
ous times (0–20 hr), aliquots (20 ng protein)
of the unbound fractions were collected
and subjected to reducing 10% SDS-PAGE,
followed by immunoblot analysis using anti-
gelatinase antibodies. Asterisks indicate the
same enzymes incubated for 20 hr in CB
buffer without resin.
(B) Gelatin zymography of bound and un-
bound fractions. Aliquots of the unbound
fractions of latent (92 and 72 kDa) and active
(82 and 62 kDa) gelatinases incubated (20 hr)
with (+) or without (2) resin 2, and aliquots of
the bound fractions (lane 1, pro-MMP-9; lane
2, MMP-9; lane 3, pro-MMP-2; lane 4, MMP-
2) eluted from the resin 2 were analyzed by
gelatin zymography.immobilization to a suitable solid support (see resin 2 in
Figure 1A). Out of several immobilization strategies, we
selected a nucleophilic opening of a Sepharose-teth-
ered oxirane ring. The choice of sulfur as a nucleophilic
species on the modified inhibitor represented a synthet-
ically viable structure alteration.
A model of a Sepharose chain was connected in silico
to the modified structural variant of the Batimastat mol-
ecule, at which point and an energy minimization was
carried. The minimum length of the linker in Sepharose
for optimum binding to MMP in solution was chosen
by systematically lengthening the chain in silico, such
that binding of MMP to the resin bound inhibitor would
not create a contact between the resin and the enzyme.
This exercise led to the structure of the desired inhibitor-
tethered resin (structure 2).
Synthetic Route to the Inhibitor-Tethered Resin
The synthetic routes for the preparation of resins 2, 5,
and 6 are given in Figure 1C. Resin 2 is hydroxamate-
based (as is Batimastat). The hydroxamate moiety is
the zinc chelating function. We have also prepared the
carboxylate-based resin 5. In this resin, we expect that
the carboxylate would coordinate to the active site
zinc ion of the MMP analogously to the case of the hy-
droxamate group, except with somewhat lower affinity.
We also set out to prepare the control resin 6, which es-
sentially contained the Sepharose resin and the linker,
after the opening of the epoxide function to eliminate
the electrophilic group.
The desired immobilized broad-spectrum inhibitor-
tethered resins 2 and 5 were prepared by shaking of Se-
pharose 6B in the presence of an excess of thiol re-
agents 3 or 4 under an atmosphere of argon. The control
resin 6 was prepared by shaking of epoxy-activated Se-
pharose 6B resin in a carbonate solution in the absence
of inhibitor.The Inhibitor-Tethered Resin Binds TIMP-free
Active Gelatinases
We first examined the ability of the inhibitor-tethered
resin to bind latent and active purified human recombi-
nant gelatinases. To this end, the enzymes were incu-
bated with resin 2 for various times (0–20 hr) and aliquots
of the unbound fractions were analyzed by immunoblot
analyses with specific anti-gelatinase antibodies. As ex-
pected, neither pro-MMP-9 nor pro-MMP-2 bound to
the resin, even after a 20 hr incubation period, and
were recovered in the unbound fraction (Figure 2A, up-
per panels). In contrast, both active MMP-9 and MMP-
2, obtained as described under Experimental Proce-
dures, bound to the resin within 30 min of the addition
of the enzymes to the resin and, consequently, were
not seen in the unbound fraction (Figure 2A, lower
panels). Gelatin zymography also demonstrated that
pro-MMP-9 (92 kDa) and pro-MMP-2 (72 kDa) were
completely recovered in the unbound fraction after incu-
bation with resin 2, while only marginal amounts of ac-
tive forms (82 and 67–60 kDa, MMP-9; 62 and 45 kDa,
MMP-2) were detectable in these fractions (Figure 2B,
left panel). The marginal active proteins that were seen
in the unbound fraction by zymography were undetect-
able by immunoblotting, as the quantities were very
small (Figure 2A, at 20 hr). In contrast, virtually all of
the active forms, but conspicuously not the zymogens,
were recovered in the bound fraction (Figure 2B, right
panel). Whereas most of the experiments described
herein have been performed with resin 2, it should be
noted that both resins 2 and 5 could be used inter-
changeably. In biological samples, the existence of
a large, diverse, and complex protein mixture in rela-
tively high concentration might potentially limit the ef-
fectiveness of active MMP binding to the resin. After
all, the solid support is a chromatographic resin that is
functionalized with the inhibitor. Furthermore, other
Chemistry & Biology
382Figure 3. The MMP-2:TIMP-2 Complex Does
Not Bind to the Inhibitor-Tethered Resin
(A and B) Active MMP-2 (200 nM) was incu-
bated without (lane 1) or with control resin
6 (lane 2) or with inhibitor-tethered resin 2
(lanes 3 and 4). MMP-2 was preincubated 1
hr with TIMP-2 (lane 4). Aliquots of the un-
bound fractions were analyzed by gelatin zy-
mography ([A], upper), and the relative en-
zyme activity was measured (B) as
described in Experimental Procedures. Total
(100%) of MMP-2 activity refers to the activ-
ity of MMP-2 (200 nM), which was incubated
under the same conditions but without
resins. Aliquots of the bound fractions were
subjected to reducing 12% SDS-PAGE, and
the gel was stained with Coomassie Brilliant
Blue ([A], lower).
(C) Serum-free conditioned media collected
from untreated (lane 1) or ConA-treated
(lane 2) HT1080 cells were incubated with
resin 2. Aliquots of the unbound and bound
fractions of untreated (lanes 3 and 5) and
ConA-treated (lanes 4 and 6) samples were
analyzed by gelatin zymography.
(D) Serum-free conditioned media collected from TPA-treated HT1080 cells were subjected to gelatin affinity chromatography. Aliquots of the
eluted proteins were subjected to reducing 15% SDS-PAGE, and MMP-2 and TIMP-2 were detected by immunoblot analysis. L = latent; I =
intermediate; A = active MMP-2.metalloenzymes might interact with the ligand and, as
such, diminish capacity for binding to the MMPs. To
overcome any such potential problem, we use an excess
of the resin and allow copious washing of the resin after
binding has taken place to make certain that the eluted
active MMPs are obtained in high purity. As will be de-
scribed subsequently here, this protocol was success-
ful. We predicted that the amounts of active MMPs in
our samples (media, extract, or homogenates) are
much lower than the estimated binding capacity for
the resins used in the quantities that have been specified
in Experimental Procedures.
Because the physiological inhibitors of MMPs, the
TIMPs, bind to the catalytic sites of the active enzymes,
they are expected to preclude resin binding. Indeed,
preincubation of active MMP-2 (62 kDa species) with
a 1.5-fold excess TIMP-2 prior to treatment with the in-
hibitor-tethered resin prevented binding of the 62 kDa
species to the resin. Consistently, the enzyme was re-
covered in the unbound fraction (Figure 3A, lane 4).
Without preincubation with TIMP-2, the active MMP-2
appeared in the bound fraction (Figure 3A, lane 3, lower
panel), as expected. Relative enzyme activity was mea-
sured in the unbound fractions by following peptide sub-
strate hydrolysis with a fluorescence spectrophotome-
ter. MMP-2 activity disappeared from the unbound
fraction as the active enzymes bound to the inhibitor-
tethered resin (Figure 3B, lane 3), but it remained in the
supernatant when the control resin 6 (without bound in-
hibitor) was used (Figure 3B, lane 2). These results fur-
ther demonstrated the specific interaction between
active MMP-2 and the immobilized inhibitor. Taken
together, these results show that resin 2 was capable
of discriminating between the latent and active gelati-
nases and between the free and TIMP-complexed en-
zymes, as was expected by the principle behind the de-
sign of the resin. It is important to note that the existing
methodology in investigations of MMP, such as immu-noblots or zymography, cannot reveal any information
on the important issue of enzymatic activity. Further-
more, even when the MMP exists in the active forms,
discernable by both immunoblotting and by zymogra-
phy, we cannot draw any conclusion as to whether the
active form is free-standing or in complex with TIMPs.
The methodology disclosed herein differentiates among
these forms, opening new avenues of investigation in
activity-based functional proteomics.
Next, we examined the ability of resin 2 to bind natural
gelatinases present in cultured cells or in human tissue
extracts (carcinoma or benign). First, we used condi-
tioned media of human HT1080 fibrosarcoma cells,
which are known to secrete progelatinases and TIMPs
[35]. Upon treatment with concanavalin A (ConA),
HT1080 cells activate pro-MMP-2 in a process that is
mediated by the membrane-anchored MT1-MMP
(MMP-14) and requires TIMP-2 [36, 37]. Active MMP-2
can then be detected in the supernatant, as shown in
Figure 3C, lane 2. We used resin 2 to analyze the distri-
bution of free versus TIMP-complex gelatinases in the
media of ConA-treated HT1080 cells. These studies
showed that pro-MMP-9, pro-MMP-2, and the interme-
diate form of MMP-2 (w68 kDa) were all recovered in
the unbound fraction, as expected (Figure 3C, lanes 3
and 4). Interestingly, relatively high levels of active
MMP-2 were also recovered in the flowthrough
(Figure 3C, lane 4), while the bound fraction contained
only trace amounts of active MMP-2 (Figure 3A, lane
6), suggesting that the presence of TIMP-2 in the culture
supernatant inhibits binding of active MMP-2 to resin 2.
To test this hypothesis, the conditioned media of
HT1080 cells were subjected to gelatin-affinity purifica-
tion to pull out all forms of gelatinases that were present.
As shown in the immunoblot in Figure 3D, the gelatin
bound fraction contained all three forms of MMP-2
(latent, intermediated, and active). In addition, TIMP-2
coeluted with the bound MMP-2 forms, which is
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383Figure 4. Binding of Active MMPs from Hu-
man Tumors to the Inhibitor Resin
(A) Gelatin zymography of carcinoma (lanes
1 and 3) and benign (lanes 2 and 4) breast
tissue extracts after incubation with resin 2.
Aliquots of unbound and bound fractions
were analyzed. The arrow indicates active
MMP-2.
(B) Immunoblot of laryngeal (lanes 1 and 2)
and breast (lanes 3 and 4) tissue extracts
(carcinoma, lanes 1 and 3; benign, lanes 2
and 4) after incubation with resin 2. Aliquots
of bound fractions were analyzed with an
antibody to MT1-MMP. C = carcinoma; B =
benign.consistent with its ability to form a complex with latent
and active MMP-2 forms. TIMP-2 would not have been
retained by the chromatographic resin if it were not al-
ready in complex with the gelatinases. These data lend
further support to the notion that a major fraction of ac-
tive MMP-2 present in the supernatant of ConA-treated
HT1080 cells is in complex with TIMP-2. These results
further show that resin 2 can differentiate between inhib-
itor-free and TIMP-complexed MMPs, and thus it is
a useful tool in identification of TIMP-free MMPs in ex-
perimental biological systems.
Identification of Gelatinases and MT1-MMP
in Human Tumor Extracts
To test the ability of resin 2 to capture active MMPs from
human tumor samples, we prepared tissue extracts
from breast and laryngeal carcinomas, as described in
Experimental Procedures. Equal protein amounts from
each extract were incubated with resin 2, and the bound
MMPs (gelatinases and MT1-MMP) were detected by
immunoblot analysis and gelatin zymography. As shown
in Figure 4A, the bound fraction of tissue extracts de-
rived from breast carcinoma showed the presence of ac-
tive MMP-2 (Figure 4A, lane 3) and active MT1-MMP
(Figure 4B, lane 3). Active MT1-MMP (w57 kDa) was
also detected in the bound fraction of extracts of laryn-
geal cancer tissue (Figure 4B, lane 1). In contrast, neither
gelatinases nor MT1-MMP was detected in the bound
fraction of extracts derived from benign breast (Figures
4A and 4B, lane 4) and laryngeal tissues (Figure 4B, lane
2). Interestingly, the unbound fractions of carcinoma
(Figure 4A, lane 1) and, to a lesser extent, that of benign
(Figure 4A, lane 2) breast tissue extracts contained sig-
nificant amounts of latent and active gelatinases, sug-
gesting that the active forms are in complex with TIMPs,
and thus they were recovered in the flowthrough. Al-
though here we have focused on detection of gelati-
nases and MT1-MMP, it is expected that other active
MMPs would also bind to the inhibitor-tethered resin,
and thus the levels of these enzymes detected in the tu-
mor extracts may be underestimated. Because tumors
are likely to express multiple MMPs, the ability to detect
TIMP-free gelatinases and MT1-MMP under those con-
ditions is consistent with the abundant expression of
these enzymes in the tumor microenvironment.
We add here that inhibitor-based affinity purification
of MMPs with simpler MMP inhibitors have been re-
ported previously, but the scope of those studies did
not envision the kinds of application undertaken in thisstudy [38–42]. Here we show for the first time that an in-
hibitor-tethered resin (resin 2) has the ability to capture
two important proteases in cancer, namely, MMP-2
and MT1-MMP, in extracts of human cancer tissues.
Most importantly, because binding of MMPs to the resin
is inhibited by TIMPs, the enzymes detected represent
active species that are free of TIMPs, and thus likely to
contribute to tumor proteolysis. It should be mentioned,
however, that differences in amounts and activation of
MMPs in tissue extracts detected by the method de-
scribed here may be affected by a variety of factors, in-
cluding the structure of the tissue, the extraction proce-
dure, the presence of detergents, and the storage of the
samples before processing, just to mention a few.
Therefore, careful attention should be given to these is-
sues before reaching conclusions on the pattern of ac-
tive MMPs present in tumor extracts.
The affinity approach described here is also useful for
isolating active MMPs from tissues and cultured cells.
Indeed, this resin has been instrumental in detection of
the soluble ectodomain of MT1-MMP in detergent-free
extracts of human breast carcinoma tissues, as we
have recently reported [43]. Recent studies have shown
that MT1-MMP is a key enzyme involved in the migration
and invasion of tumor and endothelial cells through in-
terstitial collagen matrix, and is thus essential for tumor
metastasis and angiogenesis [44–46]. Therefore, the
ability to detect active TIMP-free MT1-MMP in tumor
samples may be of clinical value. Future investigations
of this methodology with additional samples from path-
ologically characterized tumor samples are needed.
Only through such investigations can we gain a deeper
knowledge of active MMP profiles in cancer for identifi-
cation of active MMPs worthy of targeting for selective
inhibition. These efforts are especially important in light
of the fact that analyses of gene expression have been
instrumental in describing what MMP genes are upregu-
lated or downregulated [24, 44, 47]. However, there is
a clear information gap in what happens posttranscrip-
tionally. There are the issues of longevity of RNA, the fa-
cility of translocation of the MMPs to the surface of the
cell and to the milieu, the process of proteolytic activa-
tion of these enzyme, or even compartmentalization and
turnover at the protein level, not to mention inhibition by
TIMPs. All these are profoundly complicating matters
that have obscured our understanding of the critically
important contributions of MMPs to progression of can-
cer. Our studies and the general approach have the po-
tential to have an impact at the understanding of these
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instigator of manifestation of pathological outcome in
cancer. The results presented here are in line with recent
developments aimed at profiling active proteases in
biological samples [48–51], which may aid in the devel-
opment of more rational approaches to target-specific
enzymes in pathological conditions.
Significance
The integrity and normal remodeling of extracellular
matrix (ECM) is critical for the well-being of the organ-
ism. A number of pathological conditions, including
metastasis of tumors, involve remodeling of ECM, for
which matrix metalloproteinases (MMPs) have been
implicated. The functions of MMPs are regulated at
multiple levels, including zymogen activation, cellular
localization, and enzyme inhibition by tissue inhibi-
tors of metalloproteinases (TIMPs). MMPs play com-
plex roles in tumor progression. Whereas there is
compelling information, at the transcriptional level
onwhatMMPs are upregulated in cancer, the detection
of activities of MMPs is a challenge and cannot distin-
guish the functional status of these enzymes (whether
they exist as zymogens, active forms, or complexed
with TIMPs). It is the TIMP-free active species of
MMPs that are responsible for uncontrolled catalytic
activity in cancer tissues, which precipitate tumor me-
tastasis. Development of a method for selective bind-
ing of active MMPs from biological samples using
a resin-immobilized potent broad-spectrum synthetic
MMP inhibitor is described. The synthesis of resin
and its characterization with recombinant gelatinases
(MMP-2 and MMP-9), samples of cultured cell lines,
and tissue extracts are reported herein. We document
for the first time that only active MMPs and not zymo-
gen forms or MMP/TIMP complexes bound specifically
to the inhibitor-tethered resin. Benign breast tissue ex-
tracts showed no detectable bound active MMPs,
while breast carcinoma tissue extracts contained
both active MMP-2 and MMP-14, indicating that
a pool of the tumorMMPs is active, free of endogenous
protein inhibitors, and thus likely to contribute to un-
controlled proteolytic events. Monitoring the changes
in the levels of active MMPs using approaches such as
the one described in this report may serve as a valu-
able tool in both detection and determination of the
stage of the cancer and of potential outcome of cancer
treatments.
Experimental Procedures
General Preparation of the Inhibitor-Tethered Resin
Epoxy-activated Sepharose 6B (Sigma, St. Louis, MO) (0.56 g) was
washed thoroughly with distilled water (500 ml) before use. A solu-
tion of sodium bicarbonate (0.81 g) and potassium carbonate (6.91
g) in water (100 ml, pH 10.8), was prepared and degassed by sonica-
tion for 10 min under an atmosphere of argon (to remove oxygen).
The swollen resin was placed in a flask, which was then purged
with argon. The carbonate solution (5 ml) was added to the resin un-
der argon. Compound 3 (174 mg, 0.4 mmol), with K2CO3 (56 mg, 0.4
mmol) in water (1 ml), was sonicated for 10 min and then transferred
via cannula to the swollen Sepharose 6B resin. The resultant sus-
pension was swirled using a gyratory water bath shaker (model
G76; New Brunswick Scientific) under argon at 42ºC for 1 day. The
resin was filtered, washed with water (200 ml), and then washedwith methanol (200 ml). The resin was transferred to a solution of
100 mM sodium phosphate buffer (pH 8.0) and the suspension
was swirled under argon at 42ºC for 2 additional hr. The resin was fil-
tered and washed with methanol (53 40 ml), followed by five cycles
(50 ml each) of alternating washes with 100 mM sodium acetate
buffer (pH 4.0, 0.5 M NaCl) and 100 mM Tris/HCl buffer (pH 8.0, 0.5
M NaCl). Finally, the resin was washed with 0.5 M NaCl (100 ml) con-
taining 1% sodium azide, and was stored at 4ºC in the same solution.
Sodium azide was removed before use of the resin by washing with
water. Elemental analyses of the resin for both nitrogen and for sulfur
indicated incorporation of the ligand at 0.4 mmol/1 g of resin dry
weight.
Synthesis of the inhibitor-tethered resin 2 was achieved in the
same manner, following the general procedure described for the
synthesis of 5 above using intermediate 4 under nitrogen. Elemental
analyses of the resin for both nitrogen and sulfur indicated incorpo-
ration of the ligand at 0.4–0.5 mmol/1 g of resin dry weight. The prod-
uct of the control reaction (resin 6) was prepared in the carbonate
solution by agitating the epoxy-activated Sepharose 6B resin in
a shaker for 24 hr at room temperature under an atmosphere of
argon.
Cell Culture
Nonmalignant monkey kidney epithelial BS-C-1 (CCL-26) and hu-
man fibrosarcoma HT-1080 (CCL-121) cells were obtained from the
American Type Culture Collection (ATCC, Rockville, MD). Cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) and antibiotics. Human
HeLa S3 (CCL-2.2) cells were purchased from ATCC and cultured
in MEM Spinner medium (Quality Biologicals, Inc., Gaithersburg,
MD) supplemented with 5% horse serum and antibiotics.
Recombinant Proteins and Antibodies
Purified human recombinant pro-MMP-2, pro-MMP-9, and TIMP-2
were expressed in HeLa S3 cells using the vaccinia expression sys-
tem, and purified to homogeneity as previously described [52]. The
monoclonal antibodies (mAb) to human gelatinases and to TIMP-2
were previously described [53, 54]. The mAb to the catalytic domain
of MT1-MMP (LEM-2/15) [55] was a generous gift from Dr. A. Arroyo
(Hospital de la Princesa, Madrid, Spain).
Binding of Recombinant Gelatinases
to the Inhibitor-Tethered Resin
To obtain active MMP-9, purified pro-MMP-9 was incubated (37ºC,
2 hr) with a recombinant catalytic domain of MMP-3 (Calbiochem,
San Diego, CA) at 1:12 (enzyme:substrate) molar ratio in CB buffer
(50 mM Tris/HCl [pH 7.5], 150 mM NaCl, 5 mM CaCl2, and 0.02%
Brij 35). Under these conditions, all the pro-MMP-9 is converted to
the active 82 kDa species and a minor 67 and 60 kDa species. After
incubation, the active MMP-9 was isolated by gelatin-Agarose chro-
matography, as described previously [52]. Active MMP-2 (62 kDa)
was obtained by incubation (16 hr, 37ºC) of pro-MMP-2 with a re-
combinant catalytic domain of MT1-MMP (EMD Biosciences, Inc.,
La Jolla, CA) in CB buffer at a 2:1 molar ratio, as previously described
[54]. Pro-MMP-2 was also activated by incubation (2 hr, 37ºC) with
1 mM p-aminophenylmercuric acetate (APMA), followed by dialysis
against CB buffer to remove APMA, as previously described [56].
The inhibitor-tethered resin 2 was used in all experiments; however,
resin 5 works equally well.
Active MMP-2 or MMP-9 (10 nM each) were incubated (22ºC) for
various time periods with or without 20 ml of resin 2 in 0.5 ml (final vol-
ume) of CB buffer. At various times (0, 0.5, 1, 2, 4, and 20 hr), the sam-
ples were centrifuged (15,000 3 g, 1 min) and aliquots of the super-
natants (unbound fractions) were collected, mixed with reducing
Laemmli sample buffer [57], and resolved by SDS-PAGE, followed
by immunoblot analysis [37] with mAbs to human gelatinases
(mAb801 to MMP-2 and mAb209 to MMP-9). After 20 hr incubation,
the resin was washed several times with CB buffer, and the bound
proteins were eluted with Laemmli sample buffer without reducing
agents. The bound fractions were analyzed by gelatin zymography,
as previously described [58]. In some experiments, active MMP-2
was incubated (22ºC, 1 hr) with or without TIMP-2 at 1:1.5 molar ratio
(MMP-2:TIMP-2). Then, the free and TIMP-2-complexed MMP-2
(200 nM each) were each incubated (18 hr, 4ºC) with 10 ml resin 6
Metalloproteinase Inhibitor-Tethered Resin
385(control) or resin 2 in 0.6 ml CB buffer (final volume). The samples
were centrifuged (15,0003 g, 1 min), and the supernatants (unbound
fractions) were analyzed by gelatin zymography and for enzyme ac-
tivity with the peptide substrate MOCAc-Pro-Leu-Gly-Leu-
A2pr(Dnp)-Ala-Arg-NH2 (Peptides International, Louisville, KY) [53].
Substrate hydrolysis was monitored for 15 min in a Varian Cary
Eclipse fluorescence spectrophotometer at excitation and emission
wavelengths of 328 and 393 nm, respectively. After consecutive
washes of the resin with CB buffer and CB buffer supplemented
with 1 M NaCl, the bound MMP-2 was eluted with Laemmli sample
buffer. Aliquots of the samples of bound and unbound fractions
were resolved by reducing 12% SDS-PAGE, and the gel was stained
with Coomassie Brilliant Blue.
Resins 2 and 5 (in the range of 0.25–1.00 ml) were incubated (18 hr,
4ºC) with 200 nM active MMP-2 in 0.6 ml CB buffer (final volume). The
samples were centrifuged (15,0003 g, 1 min), and the supernatants
were collected and analyzed for MMP-2 activity with the fluores-
cence-quenching peptide substrate as described above.
HT1080 Cell Treatment and Analysis of Conditioned Media
HT1080 cells were treated (12 hr) with 10 mg/ml concanavalin A
(ConA; Sigma) or 100 nM phorbol ester (referred to as TPA; Sigma)
in serum-free media. The serum-free media (15 ml) were collected
and, after a brief centrifugation, were incubated with 100 ml of either
resin 2 for 18 hr at 4ºC or with gelatin-Agarose beads for 2 hr at 4ºC.
The gelatin beads were washed with CB buffer, and the bound pro-
teins were eluted with Laemmli sample buffer and subjected to im-
munoblot analysis with antibodies to MMP-2 (mAb 801) and to
TIMP-2 (mAb 101). The supernatants (unbound fractions) of resin
2-containing samples were collected after a brief centrifugation.
The resins were then thoroughly washed with CB buffer, and the
bound proteins were eluted with 25 mM Marimastat (150 ml). Aliquots
of the unbound and bound fractions were analyzed by gelatin
zymography.
Identification of Gelatinases and MT1-MMP in Human
Tumor Extracts
Samples of benign and carcinoma breast and laryngeal tissues were
collected from excess tissues sent for histopathological diagnosis
to the Department of Pathology at Harper Hospital (Detroit, MI).
The collection and use of human tissue samples was approved by
the Wayne State University Institutional Review Board according
to federal regulations (HIC no. 022803MP2E). The tissue samples
were homogenized in cold homogenization buffer (25 mM Tris/HCl
[pH 7.5], 8.5% sucrose, 50 mM NaCl, and protease inhibitors, with
the exception of metalloproteinase inhibitors), the extracts were
clarified, and the inhibitor-tethered resin was applied to the equal to-
tal protein amounts of tissue homogenate, as described previously
[43]. The protein concentration was measured in carcinoma and be-
nign homogenates (either by OD280 reading or by BCA protein assay
kit) and adjusted to equal protein amounts with homogenization
buffer. Aliquots of the eluates and the unbound fractions were
then subjected to gelatin zymography to detect the secreted active
gelatinases. Individual pairs of malignant and benign tissue samples
(derived from laryngeal or breast tissues) were homogenized in 10
vol lysis buffer (25 mM Tris/HCl [pH 7.5], 100 mM NaCl, 1% NP-40,
and protease inhibitors, with the exception of metalloproteinase in-
hibitors) to solubilize membrane-type MMPs. The lysates were
centrifuged, and the floating lipid fraction was removed. The clari-
fied tissue extracts were diluted with CB buffer, and 100 ml inhibi-
tor-tethered resin was applied at 4ºC overnight. The resin was
washed several times with CB buffer. The bound proteins were
eluted with the same volume of sample buffer. Equal aliquots of
the bound fractions from benign and carcinoma tissue samples
were resolved by reducing SDS-PAGE, followed by immunoblot
analysis using the mAb LEM-2/15 antibody against the catalytic do-
main of MT1-MMP.
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